Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2025 08:00 ET | Source: Liquidia Corporation

Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference

Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in 6MWD, cardiac effort and QoL.
August 22, 2024 06:00 ET | Source: Liquidia Corporation

Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD

Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.